Recreating the tumor microenvironment in a bilayer, hyaluronic acid hydrogel construct for the growth of prostate cancer spheroids.

Cancer cells cultured in physiologically relevant, three-dimensional (3D) matrices can recapture many essential features of native tumor tissues. In this study, a hyaluronic acid (HA)-based bilayer hydrogel system that not only supports the tumoroid formation from LNCaP prostate cancer (PCa) cells, but also simulates their reciprocal interactions with the tumor-associated stroma was developed and characterized. HA hydrogels were prepared by mixing solutions of HA precursors functionalized with acrylate groups (HA-AC) and reactive thiols (HA-SH) under physiological conditions. The resultant viscoelastic gels have an average elastic modulus of 234 ± 30 Pa and can be degraded readily by hyaluronidase. The orthogonal and cytocompatible nature of the crosslinking chemistry permits facile incorporation of cytokine-releasing particles and PCa cells. In our bilayer hydrogel construct, the top layer contains heparin (HP)-decorated, HA-based hydrogel particles (HGPs) capable of releasing heparin-binding epidermal growth factor-like growth factor (HB-EGF) in a sustained manner at a rate of 2.5 wt%/day cumulatively. LNCaP cells embedded in the bottom layer receive the growth factor signals from the top, and in response form enlarging tumoroids with an average diameter of 85 μm by day 7. Cells in 3D hydrogels assemble into spherical tumoroids, form close cellular contacts through E-cadherin, and show cortical organization of F-actin, whereas those plated as 2D monolayers adopt a spread-out morphology. Compared to cells cultured on 2D, the engineered tumoroids significantly increased the expression of two pro-angiogenic factors, vascular endothelial growth factor-165 (VEGF(165)) and interleukin-8 (IL-8), both at mRNA and protein levels. Overall, the HA model system provides a useful platform for the study of tumor cell responses to growth factors and for screening of anticancer drugs targeting these pathways.

[1]  J. Dutcher,et al.  Therapeutic potential of curcumin in prostate cancer—IV: Interference with the osteomimetic properties of hormone refractory C4‐2B prostate cancer cells , 2004, The Prostate.

[2]  Paul A. Janmey,et al.  Soft biological materials and their impact on cell function. , 2007, Soft matter.

[3]  T. McGovern,et al.  LTD₄ induces HB-EGF-dependent CXCL8 release through EGFR activation in human bronchial epithelial cells. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[4]  David J Mooney,et al.  Can tissue engineering concepts advance tumor biology research? , 2010, Trends in biotechnology.

[5]  Tobias Schmelzle,et al.  Engineering tumors with 3D scaffolds , 2007, Nature Methods.

[6]  Jorge Yao,et al.  1 a , 25-dihydroxyvitamin D 3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis , 2006 .

[7]  H. Moses,et al.  Tumor-stroma interactions. , 2005, Current opinion in genetics & development.

[8]  J. Minna,et al.  Stromal and Epithelial Expression of Tumor Markers Hyaluronic Acid and HYAL1 Hyaluronidase in Prostate Cancer* , 2001, The Journal of Biological Chemistry.

[9]  M. Klagsbrun,et al.  Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. , 1992, The Journal of biological chemistry.

[10]  Dietmar W Hutmacher,et al.  Biomaterials offer cancer research the third dimension. , 2010, Nature materials.

[11]  J. Clements,et al.  Interactions between human osteoblasts and prostate cancer cells in a novel 3D in vitro model , 2010, Organogenesis.

[12]  T. Mäkelä,et al.  Suppression of oncogenic properties of c-Myc by LKB1-controlled epithelial organization , 2007, Proceedings of the National Academy of Sciences.

[13]  S. Miyamoto,et al.  Heparin-binding epidermal growth factor–like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition , 2008, Molecular Cancer Therapeutics.

[14]  L. Chung,et al.  Targeting Angiogenic Pathways Involving Tumor–stromal Interaction to Treat Advanced Human Prostate Cancer , 1998, Cancer and Metastasis Reviews.

[15]  T. Fan,et al.  Angiogenesis in a delayed revascularization model is accelerated by angiogenic oligosaccharides of hyaluronan. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[16]  M. Casal,et al.  Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery) , 2008, Journal of tissue engineering and regenerative medicine.

[17]  K. J. Jeong,et al.  Interplay between covalent and physical interactions within environment sensitive hydrogels. , 2009, Biomacromolecules.

[18]  Jyrki Lötjönen,et al.  A Comprehensive Panel of Three-Dimensional Models for Studies of Prostate Cancer Growth, Invasion and Drug Responses , 2010, PloS one.

[19]  Jin Han,et al.  The enhancement of cancer stem cell properties of MCF-7 cells in 3D collagen scaffolds for modeling of cancer and anti-cancer drugs. , 2012, Biomaterials.

[20]  M. Klagsbrun,et al.  Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. , 1995, Molecular biology of the cell.

[21]  S. Verbridge,et al.  Tissue-engineered three-dimensional tumor models to study tumor angiogenesis. , 2010, Tissue engineering. Part A.

[22]  Dietmar W. Hutmacher,et al.  Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. , 2010, Biomaterials.

[23]  D. Hanahan,et al.  Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.

[24]  S. Glassman,et al.  Adverse Effects Associated With High-Dose Recombinant Human Bone Morphogenetic Protein-2 Use in Anterior Cervical Spine Fusion , 2006, Spine.

[25]  R. Misra,et al.  Biomaterials , 2008 .

[26]  Sang Hoon Lee,et al.  Bone regeneration using hyaluronic acid-based hydrogel with bone morphogenic protein-2 and human mesenchymal stem cells. , 2007, Biomaterials.

[27]  Chu Zhang,et al.  Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells. , 2009, Biomaterials.

[28]  Y. Mori,et al.  Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. , 2001, Circulation research.

[29]  Xinqiao Jia,et al.  Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release. , 2009, Biomaterials.

[30]  T BITTER,et al.  A modified uronic acid carbazole reaction. , 1962, Analytical biochemistry.

[31]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[32]  Glenn D Prestwich,et al.  In situ crosslinkable hyaluronan hydrogels for tissue engineering. , 2004, Biomaterials.

[33]  Glenn D Prestwich,et al.  Disulfide cross-linked hyaluronan hydrogels. , 2002, Biomacromolecules.

[34]  Donald E Ingber,et al.  Can cancer be reversed by engineering the tumor microenvironment? , 2008, Seminars in cancer biology.

[35]  M. Kurisawa,et al.  Injectable biodegradable hydrogels with tunable mechanical properties for the stimulation of neurogenesic differentiation of human mesenchymal stem cells in 3D culture. , 2010, Biomaterials.

[36]  G. Wilding,et al.  Characteristics of the glutathione/glutathione-S-transferase detoxification system in melphalan resistant human prostate cancer cells. , 1993, The Journal of urology.

[37]  Joseph W Freeman,et al.  3D in vitro bioengineered tumors based on collagen I hydrogels. , 2011, Biomaterials.

[38]  R. Jain,et al.  Micro-Environmental Mechanical Stress Controls Tumor Spheroid Size and Morphology by Suppressing Proliferation and Inducing Apoptosis in Cancer Cells , 2009, PloS one.

[39]  Meiling Jin,et al.  Potential mechanism of interleukin‐8 production from lung cancer cells: An involvement of EGF–EGFR–PI3K–Akt–Erk pathway , 2012, Journal of cellular physiology.

[40]  Luzhe Sun,et al.  Transforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling. , 2007, Cancer research.

[41]  R. Stern,et al.  Tumor Cells Enhance Their Own CD44 Cleavage and Motility by Generating Hyaluronan Fragments* , 2006, Journal of Biological Chemistry.

[42]  Paolo A. Netti,et al.  Solid stress inhibits the growth of multicellular tumor spheroids , 1997, Nature Biotechnology.

[43]  L. Matrisian,et al.  Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. , 1994, Invasion & metastasis.

[44]  M. Marberger,et al.  Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase. , 1992, European urology.

[45]  Glenn D Prestwich,et al.  Tumor engineering: orthotopic cancer models in mice using cell-loaded, injectable, cross-linked hyaluronan-derived hydrogels. , 2007, Tissue engineering.

[46]  V. Lokeshwar,et al.  HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. , 2005, Cancer research.

[47]  Valerie M. Weaver,et al.  A tense situation: forcing tumour progression , 2009, Nature Reviews Cancer.

[48]  J. Willson,et al.  Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[49]  E. Mekada,et al.  Heparin-binding EGF-like growth factor: a juxtacrine growth factor. , 2000, Cytokine & growth factor reviews.

[50]  L. Bonassar,et al.  Dense type I collagen matrices that support cellular remodeling and microfabrication for studies of tumor angiogenesis and vasculogenesis in vitro. , 2010, Biomaterials.

[51]  Hollinger,et al.  Sustained release emphasizing recombinant human bone morphogenetic protein-2. , 1998, Advanced drug delivery reviews.

[52]  P. Ongusaha,et al.  HB-EGF Is a Potent Inducer of Tumor Growth and Angiogenesis , 2004, Cancer Research.

[53]  E. Edelman,et al.  Kinetics of basic fibroblast growth factor binding to its receptor and heparan sulfate proteoglycan: a mechanism for cooperactivity. , 1992, Biochemistry.

[54]  E. Bobrovnikova-Marjon,et al.  Expression of the pro-angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endoplasmic reticulum stress , 2004, Molecular Cancer.

[55]  Xinqiao Jia,et al.  Heparin-decorated, hyaluronic acid-based hydrogel particles for the controlled release of bone morphogenetic protein 2. , 2011, Acta biomaterialia.

[56]  J. Folkman,et al.  Generation of multiple angiogenesis inhibitors by human pancreatic cancer. , 2001, Cancer research.

[57]  Tatiana Segura,et al.  The spreading, migration and proliferation of mouse mesenchymal stem cells cultured inside hyaluronic acid hydrogels. , 2011, Biomaterials.

[58]  E. Mekada,et al.  HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers. , 2011, Cancer research.

[59]  B. Foster,et al.  Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. , 1997, Cancer research.

[60]  L. Chung,et al.  Hypoxia increases VEGF-A production by prostate cancer and bone marrow stromal cells and initiates paracrine activation of bone marrow endothelial cells , 2006, Clinical & Experimental Metastasis.

[61]  A. A. Renshaw,et al.  Heparin‐binding EGF‐like growth factor in the human prostate: Synthesis predominantly by interstitial and vascular smooth muscle cells and action as a carcinoma cell mitogen , 1998, Journal of cellular biochemistry.

[62]  Gary L. Bowlin,et al.  The Use of Natural Polymers in Tissue Engineering: A Focus on Electrospun Extracellular Matrix Analogues , 2010 .

[63]  Sanjay Kumar,et al.  Elucidating the mechanobiology of malignant brain tumors using a brain matrix-mimetic hyaluronic acid hydrogel platform. , 2011, Biomaterials.

[64]  Jack Lombardi,et al.  Rheological characterization of in situ cross-linkable hyaluronan hydrogels. , 2005, Biomacromolecules.

[65]  Robert J. Linhardt,et al.  Heparin—Protein Interactions , 2002 .

[66]  J. Hubbell,et al.  The effect of the linker on the hydrolysis rate of drug-linked ester bonds. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[67]  M. Bissell,et al.  Tumor engineering: the other face of tissue engineering. , 2010, Tissue engineering. Part A.

[68]  Genee Y. Lee,et al.  The morphologies of breast cancer cell lines in three‐dimensional assays correlate with their profiles of gene expression , 2007, Molecular oncology.

[69]  I. Hampson,et al.  Angiogenesis induced by degradation products of hyaluronic acid. , 1985, Science.

[70]  G. Wilding,et al.  Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels. , 1992, Cancer research.

[71]  J. Kobler,et al.  Hyaluronic acid-based microgels and microgel networks for vocal fold regeneration. , 2006, Biomacromolecules.